var data={"title":"Cefotetan: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cefotetan: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5841?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cefotetan-drug-information\" class=\"drug drug_general\">see &quot;Cefotetan: Drug information&quot;</a> and <a href=\"topic.htm?path=cefotetan-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cefotetan: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46216290\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cefotan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046003\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Cephalosporin (Second Generation)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045995\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cefotetan-drug-information\" class=\"drug drug_general\">see &quot;Cefotetan: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> [AAP 2012]): Infants, Children, and Adolescents: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infection: 30 mg/kg/dose every 12 hours, maximum single dose: 2,000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infection: 50 mg/kg/dose every 12 hours; maximum dose: 3,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated:</b> Infants, Children, and Adolescents: IV: 20 to 40 mg/kg/dose every 12 hours. <b>Note:</b> Due to high rates of <i>B. fragilis</i> group resistance, not recommended for the treatment of community-acquired intra-abdominal infections (Solomkin 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pelvic inflammatory disease:</b> Adolescents: IV: 2,000 mg every 12 hours; used in combination with doxycycline (CDC 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis, prophylaxis for patients receiving peritoneal dialysis undergoing gastrointestinal or genitourinary procedures:</b> Infants, Children, and Adolescents: IV: 30 to 40 mg/kg administered 30 to 60 minutes before procedure; maximum dose: 2,000 mg/dose (Warady [ISPD 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis:</b> Children and Adolescents: IV: 40 mg/kg 60 minutes prior to procedure; may redose in 6 hours; maximum dose: 2,000 mg (Bratzler 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> IM, IV: Usual dose: 1,000 to 2,000 mg every 12 hours for 5 to 10 days; for life-threatening infections use 3,000 mg IV every 12 hours (maximum dose/day: 6 <b>g</b>; for IM use, manufacturer's labeling includes a maximum dose of up to 4 <b>g</b>/day). <b>Note:</b> Due to high rates of <i>B. fragilis </i>group resistance, not recommended for the treatment of community-acquired intra-abdominal infections (Solomkin 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pelvic inflammatory disease:</b> IV: 2,000 mg every 12 hours; used in combination with doxycycline (CDC 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical (perioperative) prophylaxis:</b> IV: 1,000 to 2,000 mg 30 to 60 minutes prior to surgery; when used for cesarean section, dose should be given as soon as umbilical cord is clamped</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection:</b> IM, IV: 500 mg every 12 hours or 1,000 to 2,000 mg every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: Dosage adjustments are not provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians (Aronoff 2007); <b>Note:</b> Renally adjusted dose recommendations are based on doses of 20 to 40 mg/kg/dose every 12 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &ge;30 mL/minute/1.73 m<sup>2</sup>: No adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 20 to 40 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 20 to 40 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis: 20 to 40 mg/kg/dose every 48 hours; give after dialysis on dialysis days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): 20 to 40 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): 20 to 40 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: <b>Note: </b>Renal function estimated using the Cockcroft-Gault formula:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;30 mL/minute: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 30 mL/minute: Administer usual dose every 24 hours <b>or</b> 50% of the usual dose administered every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: Administer usual dose every 48 hours <b>or</b> 25% of the usual dose administered every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Dialyzable (5% to 20%); administer 25% of the usual dose every 24 hours on days between dialysis; administer 50% of the usual dose on the day of dialysis (administer after dialysis).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147571\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cefotan: 1 g (1 ea); 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147555\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046006\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Inject deep IM into large muscle mass </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV intermittent: Infuse over 20 to 60 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV push: Inject direct IV over 3 to 5 minutes </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25188741\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vials: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Reconstituted solution is stable for 24 hours at 25&deg;C (77&deg;F),96 hours at 5&deg;C (41&deg;F) and 7 days at -20&deg;C (-4&deg;F).  In disposable glass or plastic syringes, solution is stable for 24 hours at 25&deg;C (77&deg;F) and 96 hours at 5&deg;C (41&deg;F). .</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duplex containers: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) prior to reconstitution; excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Foil strip should not be removed until ready for use; after foil strip removal, use product within 7 days. After reconstitution, use within 12 hours if stored at room temperature or within 5 days if stored under refrigeration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046005\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of susceptible lower respiratory tract, skin and skin structure, bone and joint, urinary tract, gynecologic, and intra-abdominal infections (FDA approved in adults); surgical prophylaxis (FDA approved in adults); has also been used in the prophylaxis of peritonitis in patients with peritoneal catheters undergoing gastrointestinal or genitourinary procedures</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147630\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CefoTEtan may be confused with ceFAZolin, cefOXitin, cefTAZidime, Ceftin, cefTRIAXone</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147627\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Agranulocytosis, anaphylaxis, eosinophilia, fever, hemolytic anemia, hemorrhage, increased blood urea nitrogen, increased serum creatinine, leukopenia, nausea, nephrotoxicity, phlebitis, prolonged prothrombin time, pruritus, pseudomembranous colitis, skin rash, thrombocythemia, thrombocytopenia, urticaria, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147578\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cefotetan, any component of the formulation, or other cephalosporins; previous cephalosporin-associated hemolytic anemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147559\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elevated INR: May be associated with increased INR and subsequent bleeding, especially in nutritionally deficient patients, prolonged treatment, or patients with cancer, hepatic or renal disease. Monitor coagulation parameters and manage as clinically indicated (eg, administration of phytonadione).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemolytic anemia: May rarely cause hemolytic anemia (including fatalities). Has been associated with a higher risk of hemolytic anemia relative to other cephalosporins (approximately threefold); monitor carefully during use and consider cephalosporin-associated immune anemia in patients who have received cefotetan within 2 to 3 weeks (either as treatment or prophylaxis). Discontinue drug, if applicable, and institute supportive measures as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, may occur. If an allergic reaction occurs, discontinue treatment and institute appropriate supportive measures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI disease: Use with caution in patients with a history of GI disease, particularly colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298991\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147564\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13130&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CefoTEtan may enhance the adverse/toxic effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbocisteine: CefoTEtan may enhance the adverse/toxic effect of Carbocisteine. Specifically, cefotetan may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147589\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Concurrent use with ethanol may cause a disulfiram-like reaction. Management: Monitor patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147567\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6347590\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Cefotetan crosses the placenta and produces therapeutic concentrations in the amniotic fluid and cord serum. Cefotetan is one of the antibiotics recommended for use with cesarean delivery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046002\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, prothrombin time, renal function tests; number and type of stools/day for diarrhea; signs and symptoms of hemolytic anemia; monitor for signs of anaphylaxis during first dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147558\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147577\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Widely to body tissues and fluids including bile, gallbladder, kidney, skin, tonsils, uterus, sputum, prostatic and peritoneal fluids</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 88%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 3 to 4.6 hours, prolonged in patients with moderately impaired renal function (up to 10 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IM: 1 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (51% to 81%, as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046010\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium content of 1000 mg: 3.5 mEq.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323048\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cefotan Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $47.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $95.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefoTEtan Disodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $23.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $46.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $228.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefoTEtan Disodium-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g 3.58% (1): $18.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g 2.08% (1): $25.08</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038554\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Apacef (BE, FR, LU);</li>\n      <li>Apatef (AU, DE, IT, PT);</li>\n      <li>Ceftenon (AT);</li>\n      <li>Darvilen (DE);</li>\n      <li>Kuptamete (VN);</li>\n      <li>Yamatetan (JP, KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &quot;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&quot; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotetan-pediatric-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Sexually Transmitted Diseases Treatment Guidelines, 2010,&quot; <i>MMWR Recomm Rep</i>, 2010, 59(RR-12):1-110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotetan-pediatric-drug-information/abstract-text/21160459/pubmed\" target=\"_blank\" id=\"21160459\">21160459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin C, Thomachot L, and Albanese J, &ldquo;Clinical Pharmacokinetics of Cefotetan,&rdquo; <i>Clin Pharmacokinet</i>, 1994, 26(4):248-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotetan-pediatric-drug-information/abstract-text/8013159/pubmed\" target=\"_blank\" id=\"8013159\">8013159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2010;50(2):133-164.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotetan-pediatric-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;(32 Suppl 2):S32-S86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotetan-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13130 Version 101.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F46216290\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046003\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045995\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F147571\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F147555\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046006\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F25188741\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046005\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F147630\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F147627\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F147578\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F147559\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298991\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F147564\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F147589\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F147567\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6347590\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046002\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F147558\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F147577\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1046010\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323048\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038554\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13130|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cefotetan-drug-information\" class=\"drug drug_general\">Cefotetan: Drug information</a></li><li><a href=\"topic.htm?path=cefotetan-patient-drug-information\" class=\"drug drug_patient\">Cefotetan: Patient drug information</a></li></ul></div></div>","javascript":null}